Skip to main content

Advertisement

Figure 8 | Molecular Cancer

Figure 8

From: Brg-1 mediates the constitutive and fenretinide-induced expression of SPARC in mammary carcinoma cells via its interaction with transcription factor Sp1

Figure 8

Fenretinide induces the expression of Brg-1, Brg-1 and Sp1 complex formation and the binding of Brg-1 to SPARC promoter. 4T1, 168FARN or 67NR cells were left untreated (control) or treated with the indicated doses of fenretinide for 24 hrs. Cell lysates were prepared, and assessed by Western blot analysis for Brg-1 (A) and Sp1 (B), respectively. Expression of β-actin was detected as an internal control. (C) Nuclear extracts from fenretinide-treated 4T1 cells were immunoprecipitated (IP) with antibodies against Sp1 or IgG (control). The precipitated protein complexes were subjected to SDS/PAGE and analyzed by Western blot analysis with an antibody against Brg-1 or Sp1. (D) Cross-linked chromatin derived from either fenretinide-treated or untreated 4T1 cells was immunoprecipitated with Brg-1or Sp1 antibodies or nonspecific IgG. The precipitated DNAs or input DNA were analyzed by real-time qPCR with the specific primers for the region from -201 to -23 nucleotides of the SPARC promoter. The relative occupancy level of Brg-1 or Sp1 in untreated 4T1 cells (CTR) was set as 1. Data shown are mean ± SEM (n = 3)

Back to article page